Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2025 Jun;82(6):1004-1011.
doi: 10.1016/j.jhep.2024.11.051. Epub 2024 Dec 9.

Differential HBV RNA and HBcrAg patterns in untreated patients with chronic hepatitis delta

Affiliations
Multicenter Study

Differential HBV RNA and HBcrAg patterns in untreated patients with chronic hepatitis delta

Elisabetta Degasperi et al. J Hepatol. 2025 Jun.

Abstract

Background & aims: Serum HBV RNA and hepatitis B core-related antigen (HBcrAg) levels have been proposed as useful biomarkers in the management of patients with HBV; however, their role in chronic hepatitis delta (CHD) is currently unknown.

Methods: Consecutive untreated patients with CHD were enrolled in a cross-sectional study in three EU centers. Clinical and virological characteristics were collected. Serum HBV RNA and HBcrAg levels were quantified by an automated real-time investigational assay (Cobas® 6800, Roche Diagnostics, Pleasanton, Ca, USA) and by LUMIPULSE® G HBcrAg assay (Fujirebio Europe), respectively. In 18 patients with available liver biopsies, intrahepatic analyses were performed.

Results: Overall, 240 patients with HDV were enrolled: median age 46 years, 62% male, 53% with cirrhosis, 57% nucleos(t)ide analogue treated, median ALT 70 U/L, median HBsAg 3.8 log10 IU/ml, 88% HBeAg negative, and median HDV RNA 4.9 log10 IU/ml. HBV RNA was positive (>10 copies/ml) in only 8% of patients (median 40 [13-82,000] copies/ml), whereas HBcrAg was ≥3 log10 U/ml in 77% (median 4.2 [3.0-8.0] log10 U/ml). By combining these biomarkers, three categories were identified: 23% double negative (HBV RNA/HBcrAg), 9% double positive (HBV RNA/HBcrAg) and 68% HBV RNA negative/HBcrAg positive. HBV RNA levels positively correlated with male sex and detectable HBV DNA, while positive HBcrAg correlated with higher HBsAg levels. Double-positive patients were younger, non-European, with elevated ALT and HDV RNA levels and detectable HBV DNA. Intrahepatic HDV RNA and HBV RNA were positive in most samples, while intrahepatic levels of covalently closed circular DNA were low.

Conclusions: In untreated CHD, most patients had undetectable HBV RNA but quantifiable HBcrAg ("divergent pattern") in the absence of HBeAg. Additional studies aiming to unravel the molecular mechanisms underlying these findings are warranted.

Impact and implications: Serum HBV RNA and HBcrAg (hepatitis B core-related antigen) are promising biomarkers of the transcriptional activity of covalently closed circular DNA in chronic HBV infection; however, their role in patients with HBV-HDV coinfection is unknown. At variance with what is commonly observed in HBV-monoinfected patients, HBV RNA was undetectable and HBcrAg detectable in the serum of most patients with HDV ("divergent pattern"). The understanding of the viral interplay between HBV and HDV is crucial to dissect the pathogenic mechanisms associated with the distinct phenotypes of patients with HDV.

Keywords: HBV; HBV RNA; HBcrAg; HDV; HDV RNA.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest Elisabetta Degasperi: Advisory Board: AbbVie, Roche; Speaking and teaching: Gilead, AbbVie; Travel support: Gilead, Advanz Pharma. Sabela Lens: Lecture fees from Gilead and Abbvie. Maria Francesca Cortese: Advisor for Roche. Xavier Forns: Advisor for Gilead and Abbvie. Caroline Scholtès: Lecture fees from Gilead and Abbvie; Travel support: Gilead. Caroline Charre: Lecture fees from Gilead, MSD, ViiV Healthcare; travel support: Gilead, ViiV Healthcare. Massimo Levrero: Lecture fees from Gilead, Abbvie, MSD, Roche, CLS Behring; Advisor for Roche. Pietro Lampertico: Advisory Board/Speaker Bureau for: Roche Pharma/Diagnostics, Gilead Sciences, Gsk, Abbvie, Janssen, Myr, Eiger, Antios, Aligos, Vir, Grifols, Altona, Roboscreen. Other authors report no potential conflict of interest. Please refer to the accompanying ICMJE disclosure forms for further details.

Publication types

LinkOut - more resources